MMA FREE Webinar Series – Issues involved in drug development with MDMA-assisted therapy for PTSD with Dr Rick Doblin (USA) · Mind Medicine Australia
Mind Medicine Australia logo Menu

MMA FREE Webinar Series – Issues involved in drug development with MDMA-assisted therapy for PTSD with Dr Rick Doblin (USA)

With Dr Rick Doblin (USA)

Date: Wed 26 April 2023 @ 1:00pm
Location: Webinar (online)

Don’t miss out – Get your tickets early!

Join this FREE WEBINAR presented by Dr Rick Doblin PhD (USA), Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

Science has shown psychedelic medicines offer healing, resilience and comfort where there seemed to be none. The Food and Drug Administration has named them “breakthrough therapies” for mental health conditions that lack effective treatments.

In this webinar, Dr Rick Doblin (USA) will explore the following:

  • MDMA mechanisms of action
  • Data from first Phase 3 MAPS study
  • Data from second Phase 3 MAPS study (date yet to be published)
  • Likely FDA regulations post-approval for Risk Evaluation and Mitigation Strategies (REMS)
  • Therapeutic approach used in MDMA-assisted therapy for PTSD and other therapeutic approaches being researched.

Topic: Issues involved in drug development with MDMA-assisted therapy for PTSD.

Date: Wednesday 26 April 2023

Time: 12:55pm for 1:00pm start – 2:15pm (incl Q&A) (AEST)

The presentation WILL BEGIN AT 1:00pm.

Location: Online. A link will be emailed to you with the viewing details

Don’t miss out – Get your tickets early!

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

The Presenters

Dr Rick Doblin (USA)

BSc, Ph.D

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients.

His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college or recently graduated.

Disclaimer: Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example Facebook, Instagram or Zoom private and public chat forms during a webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×